Lisa Miller - Lumos Pharma Director Relations

Insider

Lisa Miller is Director Relations of Lumos Pharma
Phone512 215 2630
Webhttps://lumos-pharma.com

Lisa Miller Latest Insider Activity

Tracking and analyzing the buying and selling activities of Lisa Miller against Lumos Pharma stock is an integral part of due diligence when investing in Lumos Pharma. Lisa Miller insider activity provides valuable insight into whether Lumos Pharma is net buyers or sellers over its current business cycle. Note, Lumos Pharma insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lumos Pharma'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Lumos Pharma Management Efficiency

The company has return on total asset (ROA) of (0.6964) % which means that it has lost $0.6964 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7283) %, meaning that it created substantial loss on money invested by shareholders. Lumos Pharma's management efficiency ratios could be used to measure how well Lumos Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Lumos Pharma currently holds 585 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Lumos Pharma has a current ratio of 17.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lumos Pharma's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jonathan MDErasca Inc
53
Luis BorgesCentury Therapeutics
62
Erin JDShattuck Labs
44
Shane WilliamsCentury Therapeutics
N/A
Daniel RyweckSilo Pharma
59
MD MBAShattuck Labs
66
Andrew MBAShattuck Labs
40
Kenneth CundyAnebulo Pharmaceuticals
66
Rex CFAAnebulo Pharmaceuticals
64
Mark WalletCentury Therapeutics
N/A
Michael DiemCentury Therapeutics
53
Gregory RussottiCentury Therapeutics
58
Brian MDRezolute
50
LLM JDRezolute
63
Abhinav ShuklaShattuck Labs
52
Steven RuhlForte Biosciences
68
David MDErasca Inc
41
CPA MSErasca Inc
55
Chandra LovejoyErasca Inc
53
Christopher RoenfeldtForte Biosciences
N/A
Fatima MDShattuck Labs
N/A
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. Lumos Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. Lumos Pharma (LUMO) is traded on NASDAQ Exchange in USA and employs 30 people.

Management Performance

Lumos Pharma Leadership Team

Elected by the shareholders, the Lumos Pharma's board of directors comprises two types of representatives: Lumos Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lumos. The board's role is to monitor Lumos Pharma's management team and ensure that shareholders' interests are well served. Lumos Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lumos Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Richard Hawkins, CEO Chairman
Lori CPA, CFO Officer
MD BA, Chief Officer
Lisa Miller, Director Relations
John McKew, Chief President
Bradley JD, Chief Counsel
Carl Langren, Consultant
BBA CPA, Chief Officer
MD FAAP, Chief Officer
Alpa Parikh, Senior Management
Eddie MBA, Corporate Controller

Lumos Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lumos Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Lumos Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lumos Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lumos Pharma will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to GameStop Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GameStop Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GameStop Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GameStop Corp to buy it.
The correlation of GameStop Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GameStop Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GameStop Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GameStop Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Lumos Stock

If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Content Syndication
Quickly integrate customizable finance content to your own investment portal